BiotechTube

MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neonate

Conditions

Neonate, Maternal Transmission, Mpox, Vaccination, Immunogenicity, Safety, Pregnancy, Postpartum

Trial Timeline

Jun 23, 2025 → May 1, 2027

NCT ID
NCT06844500

About MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)

MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP) is a phase 3 stage product being developed by Bavarian Nordic for Neonate. The current trial status is active. This product is registered under clinical trial identifier NCT06844500. Target conditions include Neonate, Maternal Transmission, Mpox.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06844500Phase 3Active

Competing Products

1 competing product in Neonate

See all competitors
ProductCompanyStageHype Score
DexmedetomidineOrion CorporationPhase 3
74

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
Ad26.ZEBOV + MVA-BN-FiloPhase 3
74